Estrella Immunopharma Files 8-K
Ticker: ESLAW · Form: 8-K · Filed: Dec 4, 2025 · CIK: 1844417
Sentiment: neutral
Topics: corporate-information, name-change
Related Tickers: ESLA
TL;DR
Estrella Immunopharma (ESLA) filed an 8-K on 12/4/25, confirming its identity and address.
AI Summary
On December 4, 2025, Estrella Immunopharma, Inc. filed an 8-K report. The filing indicates the company's fiscal year ends on December 31st and provides its business address as 5858 Horton Street, Suite 370, Emeryville, CA 94608. The company was formerly known as TradeUP Acquisition Corp. before changing its name on February 4, 2021.
Why It Matters
This 8-K filing provides updated corporate information for Estrella Immunopharma, Inc., including its name, former name, and address, which is relevant for investors tracking the company's official disclosures.
Risk Assessment
Risk Level: low — This filing is primarily administrative, confirming corporate details rather than announcing significant financial events or strategic shifts.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- December 4, 2025 (date) — Date of earliest event reported
- 5858 Horton Street, Suite 370, Emeryville, CA 94608 (address) — Business address
- TradeUP Acquisition Corp. (company) — Former company name
- February 4, 2021 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report current information about Estrella Immunopharma, Inc., including its name, address, and former name.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 4, 2025.
What is Estrella Immunopharma, Inc.'s business address?
Estrella Immunopharma, Inc.'s business address is 5858 Horton Street, Suite 370, Emeryville, CA 94608.
What was Estrella Immunopharma, Inc. formerly known as?
Estrella Immunopharma, Inc. was formerly known as TradeUP Acquisition Corp.
When did the company change its name from TradeUP Acquisition Corp.?
The company changed its name from TradeUP Acquisition Corp. on February 4, 2021.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-04 09:21:19
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
Filing Documents
- ea0268496-8k_estrella.htm (8-K) — 31KB
- ea026849601ex99-1_estrella.htm (EX-99.1) — 12KB
- 0001213900-25-118097.txt ( ) — 255KB
- esla-20251204.xsd (EX-101.SCH) — 4KB
- esla-20251204_def.xml (EX-101.DEF) — 26KB
- esla-20251204_lab.xml (EX-101.LAB) — 36KB
- esla-20251204_pre.xml (EX-101.PRE) — 25KB
- ea0268496-8k_estrella_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On December 4, 2025, Estrella Immunopharma, Inc. (the "Company") issued a press release titled "Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Estrella Immunopharma, Inc., dated December 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Cheng Liu Name: Cheng Liu Title: Chief Executive Officer Date: December 4, 2025 2